Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents

Area of Science:

• Urology
• Pharmacology
• Men's Health

Background:

• Erectile dysfunction (ED) pharmacotherapy has seen significant advancements.
• The introduction of oral agents like sildenafil has increased treatment seeking and physician involvement.
• Research in ED is rapidly expanding globally.

Purpose of the Study:

• To review recent developments in ED pharmacotherapy.
• To highlight next-generation phosphodiesterase inhibitors.
• To summarize evolving research into centrally acting agents for potential combination therapy.

Main Methods:

• Literature review of recent information on ED pharmacotherapy.
• Focus on novel oral therapies and phosphodiesterase inhibitors.
• Summary of pre-clinical and early-phase registration trials.

Main Results:

• Sildenafil has expanded treatment access for erectile dysfunction.
• Novel oral therapies are in development with promises of improved efficacy and safety.
• Centrally acting agents are an area of evolving research.

Conclusions:

• The field of erectile dysfunction treatment is advancing rapidly.
• Next-generation therapies, including phosphodiesterase inhibitors and centrally acting agents, show promise.
• Combination therapy may offer improved outcomes for men with ED.